Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.
about
Guidance on vaccination of HIV-infected children in Europe.Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness.Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.Characterization of 19A-like 19F pneumococcal isolates from Papua New Guinea and FijiRoutine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens.Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introductionHyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.Prevnar 13, the new 13-valent pneumococcal conjugate vaccine.New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.Pneumococcus with the "6E" cps Locus Produces Serotype 6B Capsular Polysaccharide.Carrier priming to improve pneumococcal disease control and reduce the international program's cost in children.Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea.
P2860
Q34251138-389B6DE4-CFFA-4BC6-8126-4982F268239FQ34291235-CB24EEE5-54E4-4E30-B58D-13D7364A8A07Q34998490-8215C61C-52C0-40CA-B79A-66BD859EB056Q35042732-0296457D-ABFB-44F2-A132-983DD39ABD6AQ35868890-73E93576-9CBC-4007-9ECF-820B660E6B85Q35990339-2FAC11A2-55C4-4F61-93C1-84229869931EQ36105725-3C269E71-C3F3-4F3C-970F-CCD16863D9AFQ37162391-A95F0384-AE99-477D-A49F-20F1ADA57719Q37857246-D1F9C86D-A7B1-49CF-B561-3B501658A9C3Q37951905-8BAC368E-D8E9-42E3-831D-7E15F82348A5Q38121956-18DD9724-FBE9-4399-B0B2-68B31D7ABDEFQ39576336-D6DFDF6E-FAAD-4FB9-B602-0E57F4A0EA76Q42338463-898EC317-C004-4F5E-92E5-769416A99C02Q47098110-166A1F59-4FFF-4084-8239-2236301B4B7E
P2860
Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Opsonophagocytic activity foll ...... e vaccine at 12 months of age.
@ast
Opsonophagocytic activity foll ...... e vaccine at 12 months of age.
@en
Opsonophagocytic activity foll ...... e vaccine at 12 months of age.
@nl
type
label
Opsonophagocytic activity foll ...... e vaccine at 12 months of age.
@ast
Opsonophagocytic activity foll ...... e vaccine at 12 months of age.
@en
Opsonophagocytic activity foll ...... e vaccine at 12 months of age.
@nl
prefLabel
Opsonophagocytic activity foll ...... e vaccine at 12 months of age.
@ast
Opsonophagocytic activity foll ...... e vaccine at 12 months of age.
@en
Opsonophagocytic activity foll ...... e vaccine at 12 months of age.
@nl
P2093
P2860
P1433
P1476
Opsonophagocytic activity foll ...... e vaccine at 12 months of age.
@en
P2093
E K Mulholland
F M Russell
J R Carapetis
L Tikoduadua
L Waqatakirewa
M L K Tang
P V Licciardi
P2860
P304
P356
10.1016/J.VACCINE.2010.10.046
P407
P577
2010-10-31T00:00:00Z